

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Catherine ROUGEOT, et al.

SERIAL NO: 10/620,462

GAU:

FILED: July 17, 2003

EXAMINER:

FOR: THERAPEUTIC USE OF THE SMR1 PROTEIN AND ACTIVE DERIVATIVES THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☐ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☒ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Roland E. Martin  
Registration No. 48,082

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

240156US0DIV

SERIAL NO.

10/620,462

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Catherine ROUGEOT, et al.

FILING DATE

July 17, 2003

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
KAC	AA	6,589,750	07-08-03	ROUGEOT et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	
	AX	
	AY	
	AZ	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

/Karen A. Canella, Ph.D./

Date Considered

06/26/2006

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**LIST OF RELATED CASES**

<u>Docket Number</u>	<u>Serial or Patent Number</u>	<u>Filing or Issue Date</u>	<u>Inventor/ Applicant</u>
240988US-0-CIP	10/024,535	12/21/01	MARCEL, et al.
00660-0158-0 PCT	09/367,703	10/13/99	ROUGEOT, et al.
238578US-0-X PCT	10/451,064	6/20/03	ROUGEOT, et al.
239675US-0	6,589,750	7/8/03	ROUGEOT, et al.
239676US-0-DIV	10/435,564	5/12/03	ROUGEOT, et al.
239682US-0-CONT	10/315,445	12/10/02	MARCEL, et al.
240156US-0-DIV*	10/620,462	7/17/03	ROUGEOT, et al.

\*Present Application; listed for information  
NFO/wal

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Catherine ROUGEOT, et al.

SERIAL NO: New Application

GAU:

FILED: Herewith

EXAMINER:

FOR: THERAPEUTIC USE OF THE SMR1 PROTEIN AND ACTIVE DERIVATIVES THEREOF

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449 and cited in the attached International Search Report. Copies of the listed references were previously filed in PCT/EP98/00956 filed on February 19, 1998.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
Norman F. Oblon

Registration No. 24,618



22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Thomas M. Cunningham  
Registration No. 45,394

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. <b>240156US0DIV</b>		SERIAL NO. <b>New Application</b>	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT <b>Catherine ROUGEOT, et al.</b>			
				FILING DATE <b>Herewith</b>		GROUP	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
KAC	AA	5 219 548	6/15/93	YANG, David J. et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES                  NO		
KAC	AO	WO 90 03981	4/19/90	WIPO			
KAC	AP	WO 95 00848	1/5/1995	WIPO			
KAC	AQ	EP 0 240 975	10/14/87	EP			
	AR						
	AS						
	AT						
	AU						
	AV						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
KAC	AW	ROUGEOT et al., "Selective processing of submandibular rat 1 protein at dibasic cleavage sites," EUR. J. BIOCHEM., vol. 219, 1994, pp. 765-773.					
KAC	AX	PURDIE et al., "Effects of danazol on mineral homeostasis in normal postmenopausal women: preliminary communication," JOURNAL OF ROYAL SOCIETY OF MEDICINE, vol. 80, no. 11, 1987, pp. 681-682.					
KAC	AY	ROUGEOT et al., "TARGETS FOR SMR1-PENTAPEPTIDE SUGGEST A LINK BETWEEN THE CIRCULATING PEPTIDE AND MINERAL TRANSPORT," AM. J. PHYSIOLOGY, vol. 273, no. 4 PT 2, October 1997, pp. R1309-1320.					
KAC	AZ	SINGER et al., "Recent evolution of genes encoding the prohormone-like protein SMR1 in the rat submandibular gland," DNA CELL BIOLOGY, vol. 14, no. 2, 1995, pp. 137-144.				<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner <b>/Karen A. Canella, Ph.D./</b>					Date Considered <b>06/26/2006</b>		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 240156US0DIV		SERIAL NO. New Application	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Catherine ROUGEOT, et al.			
				FILING DATE Herewith		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
KAC	AAA	COURTY et al., "Episodic evolution and rapid divergence of members of the rat multigene family encoding the salivary prohormone-like protein SMR1," MOLECULAR BIOLOGY AND EVOLUTION, vol. 12, no. 6, 1996, pp. 758-766.					
KAC	AAB	DREWS R et al., "PROTEOLYTIC MATURATION OF PROTEIN C UPON ENGINEERING THE MOUSE MAMMARY GLAND TO EXPRESS FURIN," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 23, November 1995, pp. 10462-10466.					
KAC	AAC	DRUCKER et al., "Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase," Nature Biotechnology, (Abstract), 1997.					
	AAD						
	AAE						
	AAF						
	AAG						
	AAH						
	AAI						
	AAJ						
	AAK						
	AAL						
	AAM						
	AAN						
	AAO						
	AAP						
	AAQ						
Examiner /Karen A. Canella, Ph.D./				Date Considered 06/26/2006			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							